About Omeros
Omeros is a publicly listed company based in Seattle (United States) founded in 1994. Drugs for inflammation, coagulopathies, and CNS disorders are developed. Omeros has raised $63.28 million across 33 funding rounds from investors including East West Bank, NIH and Grosvenor Capital Management. The company has 202 employees. Omeros has completed 1 acquisition, including Nura Inc. Its chief executive, as recorded, is Greg Demopulos. Its website omeros.com draws about 16 thousand monthly visits. Its focus areas include Diversified Pharmaceuticals.
Company details
Omeros is a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery platform, the companys first drug product, Omidria (phenylephrine and ketorolac injection) has been approved by the FDA for use during cataract surgery or intraocular lens (IOL) replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. In the European Union, the European Commission (EC) has approved Omidria for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain. Omeros has five clinical-stage development programs focused on: complement-related thrombotic microangiopathies; Huntingtons disease, schizophrenia, and cognitive impairment; addictive and compulsive disorders; and preventing problems associated with urologic surgical procedures. In addition, Omeros has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.
- Headquarters Seattle, United States
- Employees 202
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website omeros.com
- Social LinkedIn X
- Legal Name Omeros Corporation
- Net Profit-$3.35 M (USD)97.86as on Dec 31, 2025
- EBITDA-$121.83 M (USD)27.61as on Dec 31, 2025
- Total Equity Funding$63.28M (USD)
in 33 rounds
- Latest Funding Round$6.69M (USD), Grant
Apr 2023
- InvestorsEast West Bank
& 15 more
- Employee Count202
- Investments & Acquisitions
Funding Insights of Omeros
Omeros has successfully raised a total of $63.28M across 33 strategic funding rounds. The most recent funding activity was a Grant round of $6.69 million completed in April 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $63.28M
- Total Rounds 33
- Last Round Grant — $6.69M
- Investors Count 16
Latest 10 of 33 funding rounds of Omeros with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2023 | $6.69M | Grant | – | – | |
| Nov 2018 | $210M | Post-IPO | – | – | – |
| Apr 2018 | $45M | Debt – Venture | – | – | |
| Jan 2016 | $50M | Debt – Conventional | – | – | |
| Mar 2014 | $32M | Debt – Conventional | – | – | |
| May 2013 | $16.2M | Post-IPO | – | – | – |
| Sep 2012 | $697,020 | Grant | – | – | |
| Jul 2012 | $193,002 | Grant | – | – | |
| Jun 2012 | $193,002 | Grant | – | – | |
| Feb 2012 | $1.04M | Grant | – | – |
16 investors in total: 16 institutional.
Investors in Omeros
Omeros has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include East West Bank, NIH and Grosvenor Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
CRG is recognized as a premier healthcare investment partner. | crglp.com | Houston, United States | ||
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Private debt funds are managed across multiple sectors. | 2008 | midcapfinancial.com | Bethesda, United States | |
| bluecrestcapitalfinance.com | ||||
Growth capital is provided by Aravis for Swiss high-tech companies. | aravis.ch | Switzerland | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
| southerncrossgroup.com | ||||
| trevihealth.com | ||||
Early-stage investments are made in Washington-based startups by WRF Capital. | wrfcapital.com | Seattle, United States |
Investor details for Omeros
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Omeros
105 people are tracked at Omeros (41 in leadership, 6 in board & advisors, 58 in team); the tracked headcount is 202.
| Name | Role | Group |
|---|---|---|
Greg Demopulos | CEO | Leadership |
Peter W. Williams | Vice President, Human Resources | Leadership |
Gregory A. Demopulos | Chairman & CEO | Leadership |
George A. Gaitanaris | Chief Scientific Officer | Leadership |
Timothy M. Duffy | Vice President, Business Development | Leadership |
Catherine A. Melfi | Chief Regulatory Officer | Leadership |
Peter B. Cancelmo | Vice President, General Counsel and Corporate Secretary | Leadership |
J. Steven Whitaker | Chief Medical Officer | Leadership |
Steve Terreri | Regional Business Director | Leadership |
Michael T. | Senior Director | Leadership |
Christopher S. Bral | Vice President, Nonclinical Development | Leadership |
Brenda Baker Mba | Director Compensation, Benefits, HRIS | Leadership |
Peter Nollert | Associate Vp, Structural Biology | Leadership |
Alexander Gragerov | Senior Director Research | Leadership |
Peter M. | Regional Business Director, BMT | Leadership |
Matt A. | Sr. Director, Medical Science Liaisons | Leadership |
Steve Whitaker | Vice President, Clinical Development | Leadership |
Angela Sciarra | Vice President, Market Access And Value | Leadership |
Bill Woodman | Vice President Of Sales | Leadership |
Ly Phan-Schupp | Vice President, Clinical Operations | Leadership |
85 more people are available in the full profile.
Complete people profiles for Omeros
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Omeros
Omeros is a publicly listed company on the NASDAQ with ticker symbol OMER in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Oct 2009
- Listed onNASDAQ: OMER
- Listed entityOmeros Corporation
- Exchange sectorHealth technology
- ISINUS6821431029
- Share price$18.88 (-3.82% on the day) · 2026-10-13
- Market capitalisation$1.37B
- Price to earnings13.1
- EPS (diluted, trailing year)$1.44
- Volume (last session)994,056
Financials of Omeros
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$3.4M | -$121.8M | |
| 2024 | -$156.8M | -$168.3M | |
| 2023 | -$117.8M | -$163.6M | |
| 2022 | $47.4M | -$162.4M | |
| 2021 | -$111.4M | -$172.2M |
Detailed financial statements for Omeros
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Omeros
Omeros has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Nura Inc.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Steel structures are assembled, plants maintained, and cranes rented. | nurainc.com | Seattle, United States | 2003 | Sep 2006 | •••• |
Complete acquisition details for Omeros
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Omeros
5 dated milestones of Omeros across 29 years, from founding to its latest funding, stage changes and deals.
- Founded Omeros is founded.
- Funding First funding round.
- Acquisition Acquires Nura Inc.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $6.7M.
Web traffic of Omeros
The website of Omeros (omeros.com) receives about 15.6K visits a month and ranks #1,695,799 among all websites worldwide, #2,286 in Biotechnology and Pharmaceuticals.
- Monthly visits15.6K
▲ 10.6% vs previous month
- Unique visitors6.5K
per month
- Global rank#1,695,799
among all websites
- Category rank#2,286
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit2.0
- Average visit1 min 44 sec
- DevicesDesktop 45% · Mobile 55%
Websites whose visitors overlap most with Omeros. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| dendreon.com | 100% | 17.6K | #885,568 | View details | |
| rarecyte.com | 96% | 3.2K | #5,681,690 | View details | |
| shapetx.com | 95% | 2K | #11,569,347 | View details | |
| sobi.com | 83% | 90.6K | #498,273 | View details | |
| lundbeck.com | 80% | 137.6K | #280,857 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 17 similar websites and full traffic analytics for Omeros
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 17 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Omeros (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Omeros
Complete news archive for Omeros
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Omeros
Omeros was founded in 1994 and raised its 1st funding round 6 years after it was founded.
Omeros is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Greg Demopulos is the CEO of Omeros, as recorded in our data.
Omeros is a funded company, having raised a total of $63.28M across 33 funding rounds to date. The company's 1st funding round was a Grant of $1.04M, raised on Jul 2000.
Omeros has 202 employees.
Omeros is a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery platform, the companys first drug product, Omidria (phenylephrine and ketorolac injection) has been approved by the FDA for use during cataract surgery or intraocular lens (IOL) replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. In the European Union, the European Commission (EC) has approved Omidria for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain. Omeros has five clinical-stage development programs focused on: complement-related thrombotic microangiopathies; Huntingtons disease, schizophrenia, and cognitive impairment; addictive and compulsive disorders; and preventing problems associated with urologic surgical procedures. In addition, Omeros has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.
Yes, Omeros is publicly traded on NASDAQ under the ticker symbol OMER.
Omeros has made 1 acquisition, including Nura Inc.
Omeros has 16 investors. Key investors include East West Bank, NIH, Grosvenor Capital Management, HHS, and MidCap Financial.